01 Sep 2025 07:00 CEST

Issuer

AKER BIOMARINE ASA

Aker BioMarine has secured new business with a customer for the supply of
Superba Krill Oil. The expected revenue is estimated to position said customer
among the company’s three largest. Supply of volumes are anticipated to commence
in the fourth quarter of 2025.

“Over the past years, we have built a strong global sales team that continues to
deliver results, supported by a diversified customer base and solid growth
momentum across all markets. The combination of many smaller wins and larger
opportunities like this is what drives sustainable, long-term growth for Superba
Krill Oil,” said Matts Johansen, CEO of Aker BioMarine.

For further information, please contact
Christopher Robin Vinter, VP Strategic Finance & IR
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine, and
PL+, as well as the consumer brand, Kori Krill. The innovative approach also
extends into the spin-offs AION (reduce and recycle plastic waste across
industries) and Understory (a protein brand). Aker BioMarine is listed on the
Oslo Stock Exchange (AKBM). More information is available at
www.akerbiomarine.com.


Source

Aker BioMarine ASA

Provider

Oslo Børs Newspoint

Company Name

AKER BIOMARINE ASA, Aker Biomarine ASA 24/27 FRN C

ISIN

NO0010886625, NO0013326025

Symbol

AKBM

Market

Euronext Oslo Børs